<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915067</url>
  </required_header>
  <id_info>
    <org_study_id>1936-201-008</org_study_id>
    <nct_id>NCT03915067</nct_id>
  </id_info>
  <brief_title>BOTOX for the Treatment of Platysma Prominence</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOXÂ® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of BOTOX in adults with moderate to severe platysma
      prominence
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Actual">April 16, 2020</completion_date>
  <primary_completion_date type="Actual">April 16, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of improvement as rated by investigator using the clinician platysma scale</measure>
    <time_frame>14 Days</time_frame>
    <description>The investigator evaluates the participant's Platysma Prominence severity using a 5-grade scale where 1 = minimal and 5 = extreme</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on incidence of adverse events</measure>
    <time_frame>4 Months</time_frame>
    <description>Number of Patients who experienced one or more Treatment Emergent Adverse Event (TEAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on change from baseline in pulse rate</measure>
    <time_frame>4 Months</time_frame>
    <description>Participants with a clinically relevant change from baseline in pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on change from baseline in systolic and diastolic blood pressure (BP)</measure>
    <time_frame>4 Months</time_frame>
    <description>Participants with a clinically relevant change from baseline in systolic and diastolic BP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of BOTOX compared with placebo in participants with moderate to severe platysma prominence based on change from baseline in respiration rate</measure>
    <time_frame>4 Months</time_frame>
    <description>Participants with a clinically relevant change from baseline in respiration rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of improvement as rated by participant using the participant platysma scale</measure>
    <time_frame>14 Days</time_frame>
    <description>The participant evaluates their own Platysma Prominence severity using a 5-grade scale where 1 = minimal and 5 = extreme</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Platysma Prominence</condition>
  <arm_group>
    <arm_group_label>BOTOX High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BOTOX High Dose will be injected into the platysma muscle on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BOTOX Low Dose will be injected into the platysma muscle on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be injected into the platysma muscle on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX High Dose</intervention_name>
    <description>BOTOX will be injected into the platysma muscle</description>
    <arm_group_label>BOTOX High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX Low Dose</intervention_name>
    <description>BOTOX will be injected into the platysma muscle</description>
    <arm_group_label>BOTOX Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be injected into the platysma muscle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female participants willing to minimize the risk of inducing pregnancy for the
             duration of the clinical study and follow-up period

          -  A female participant is eligible to participate if she is not pregnant (has a negative
             urine pregnancy result prior to randomization), not breastfeeding, and at least one of
             the following conditions applies:

               1. Not a woman of childbearing potential (WOCBP) OR

               2. A WOCBP who agrees to follow the studies contraceptive guidance during the
                  treatment and follow-up period through study exit.

          -  Capable of giving signed informed consent, which includes compliance with the
             requirements and restrictions listed in the ICF and in this study's protocol

        Exclusion Criteria:

          -  Any medical condition that may put the participant at increased medical risk with
             exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome,
             amyotrophic lateral sclerosis, or any other condition that might interfere with
             neuromuscular function

          -  Participant has an anticipated need for treatment with botulinum toxin of any serotype
             for any indication during the study (other than study intervention)

          -  Anticipated need for surgery or overnight hospitalization during the study

          -  Current enrollment in an investigational drug or device study or participation in such
             a study within 30 days of entry into this study

          -  Females who are pregnant, nursing, or planning a pregnancy during the study

          -  Known immunization or hypersensitivity to any botulinum toxin serotype

          -  History of alcohol or drug abuse within 12 months of the study

          -  Participant has tattoos, jewelry, or clothing that cannot be removed, and that obscure
             the neck
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Tong</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skincare &amp; Laser Physicians of Beverly Hills</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Research Institute LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeNova Research dba Arano, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser Skin and Vein</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Dermatology, Cosmetics, &amp; Laser Surgery</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Practice of Brian S. Biesman, MD</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shannon Humphrey Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Derm</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermetics</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sweat Clinics of Canada</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R 3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bertucci MedSpa</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>L4L 8E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication, and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

